Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Treasury Shares (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Treasury Shares for 6 consecutive years, with $852000.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 752.0% to $852000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $852000.0 through Dec 2025, up 752.0% year-over-year, with the annual reading at $852000.0 for FY2025, 752.0% up from the prior year.
  • Treasury Shares hit $852000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $917000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.5 million in Q3 2022 to a low of $5000.0 in Q3 2023.
  • Historically, Treasury Shares has averaged $386666.7 across 5 years, with a median of $181000.0 in 2021.
  • Biggest five-year swings in Treasury Shares: tumbled 99.66% in 2023 and later surged 15020.0% in 2025.
  • Year by year, Treasury Shares stood at $121000.0 in 2021, then tumbled by 81.82% to $22000.0 in 2022, then tumbled by 77.27% to $5000.0 in 2023, then skyrocketed by 1900.0% to $100000.0 in 2024, then skyrocketed by 752.0% to $852000.0 in 2025.
  • Business Quant data shows Treasury Shares for IMDX at $852000.0 in Q4 2025, $917000.0 in Q3 2025, and $792000.0 in Q2 2025.